The MICROS Infusion System is an intravenous drug delivery system that is capable of control release of more than 100 injectable drugs for treatment of infectious diseases, cancer chemotherapy and cardiovascular diseases.
The MICROS™ is made of a patented nano-biomembrane controlled release system that can be customized for the IV administration of NA-704 for treatment of neurological diseases.
The MICROS™ Infusion System has been approved by the United Stated Food and Drug Administration (FDA) for marketing in the USA.
MICROS™ Infusion System Diagram
* An advanced infusion system for more than 100 injectable drug formulations for treatment of infectious diseases, cancer chemotherapy, cardiovascular and neurological diseases.
* The MICROS™ is made with a patented nano-membrane, which provides excellent accuracy and high efficiency exceeding 97%.
* Ensure aseptic system with built-in nanoscale membrane (50 nanometers) eliminating particulates, bacteria, and endotoxin.
* The MICROS™ can be prefilled with a customized dosage of NA-704 to be available as a premixed and ready to for Alzheimer patients at home
* A unique disposable infusion system that can be used for multiple doses up to 3 days.
* A cost-effective drug delivery system that can save a 300 bed hospital more than $200,000 per year in intravenous products.
For further information about our products, please contact us. Contact us
Traneuroci™ or NA-831 provides neuroprotection and catalyzing the regeneration of new neurons. Oral 30 mg per day for patients with early onset of Alzheimer’s Disease. NA-831 is manufactured by NeuroActiva, a subsidiary of Biomed.
Learn more
In Alzheimer’s patients, the ability to regenerate new neurons in the hippocampus is impaired, causing memory loss and cognitive disorders. NA-831 facilitates neurogenesis restoring memory loss and improve cognitive functions.
Learn more
Biomed is conducting Phase 3 clinical trials of NA-831 for the treatment and prevention of Alzheimer’s disease. We also conduct Phase 2/3 trials of NA-831 in combination with Atazanavir, Remdesivir, and Dexaneurosone and Ivermectin for treating Covid-19
Learn more
Vineurocin (NA-704) is an injectable drug, to regenerate new neurons, and reducting of muscular spasticity, a strong candidate for treatment of Alzheimer’s disease and Parkinson’s disease. NA-704 can be administered with the MICROS. NA-704 is in the Phase 1 safety studies.
Learn more
Combination therapy of NA-831 and an antiviral drugs such as Atazanavir, Remdesivir (Gilead Sciences) and anti-inflammatory such as Dexaneurosone and Ivermectin can enhance the effectiveness of the treatment of Covid-19.
Learn more